

accompanying application as follows:

Please add the Abstract attached on a separate sheet. ✓

In the Claims

Please cancel Claims 17, 18, 28, 29, 31 and 32 (without prejudice); enter the indicated amendments to Claims 2, 4 to 7, 9 to 16, 19 to 25, 27 and 33; and enter new Claims 34 to 36. ✓ Directions for amendment of claims are indicated on the copy of the attached hand amended ("marked up") original claims, showing in manuscript the amendments that have been made and the origins of the new claims. Clean forms of new and rewritten claims are included in the attached "Clean Set of Claims" document. ✓

Remarks

This application seeks protection for certain novel compounds that are inhibitors of the serine protease, Factor Xa, and are useful for the treatment of thrombotic disorders. It is the national stage of an international application, the claims of which were drafted in accordance with international practice.

Applicants now wish to amend the application to bring it into conformity with United States patent practice.

For the assistance of the Examiner, a copy of the original claims is attached, as noted above, showing in manuscript the amendments that have been made.

Claims 17, 18, 28, 29, 31 and 32 have been cancelled, without prejudice.

Claims 2, 4 to 6, 9 to 13, 15 to 16, 19 to 24, 27 and 33 have been rewritten in single dependent form.

Claim 2 has been further amended by inserting the value "piperidin-4-yl (which may bear a 1-methyl

substituent,)" in the definition of CHReRf before "or indan-2-yl". Basis for this amendment may be found in the corresponding passage at page 8, lines 22 to 23 of the description.

Claim 7 has been amended by inserting a definition for L, based upon page 11, line 16.

Claim 14 now depends from any one of claims 1 to 13, 15 to 16 and 19 to 22. Claim 25 now depends from claim 14.

New claim 34 is based upon Claim 26 and is directed to a single compound, 1-(Indole-6-carbonyl-D-phenylglyciny)-4-(1-methylpiperidin-4-yl)piperazine and its physiologically tolerable salts. New Claim 35 is based upon Claim 27, and is directed to a pharmaceutical composition comprising a compound of new Claim 34. Similarly, new Claim 36 is based upon Claim 30, and is directed to a method of combating a thrombotic disorder using a compound of new Claim 34.

For the convenience of the Examiner, it is noted that the compounds of new Claim 34 correspond with formula (I) in Claim 1 in which R_2 is indol-6-yl, X-X is CONH , Y is CH and has the D-configuration, Cy is phenyl and R_r is $-\text{CHReRf}$ in which CHReRf is piperidin-4-yl that bears a methyl group at the 1-position. Currently Claims 1, 2, 7 to 16, 19 to 22, 24 to 27, 30 and 34 to 36 read on these compounds. Claim 33 reads on an intermediate useful in the preparation of these compounds.

Favorable consideration of the application is requested.

10030187-020402

Respectfully submitted,



Hay, Martin Alexander

Agent for Applicants

Registration No. 39,459

Phone: 011 44 1625 500057

Martin A. Hay & Co.,
13 Queen Victoria Street
Macclesfield
Cheshire
SK11 6LP
UNITED KINGDOM

February 1, 2002

Attachments: Abstract on separate sheet
 Hand-amended (marked-up) Claims
 Clean Pending Claims

10030187.020402

- $$\begin{array}{c} \text{Cy} \\ | \\ \text{R}_2 - \text{X} - \text{X} - \text{Y} - \text{L} - \text{Lp(D)}_n \end{array}$$

wherein:

each R_{1a} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R_1 is as defined for R_{1a} , provided that R_1 is not

unsubstituted aminoalkyl;

Y (the α -atom) is a nitrogen atom or a CR_{1b} group;

Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, optionally substituted by groups

5 R_{3a} or $R_{3i}X_i$;

each R_{3a} independently is R_{1c} , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkylimidazolyl, thiazolyl, alkylthiazolyl, alkyloxazolyl, oxazolyl, alkylsulphonamido,


10 alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula $-C(X^3)N(R^{11})R^{12}$ (wherein X^3 is O or S; and R^{11} and R^{12} are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group), or $-OCH_2O-$ which is bonded to two adjacent ring atoms in Cy;

X_i is a bond, O, NH or CH_2 ;

R_{3i} is phenyl, pyridyl or pyrimidinyl optionally substituted by R_{3a} ;

20 R_{1b} , R_{1c} and R_{1j} are as defined for R_{1a} ; and

$-L-Lp(D)_n$ is of the formula:



in which R_r is $-(CH_2)_c-R_c$, $-CHR_eR_f$, $-CH_2-CHR_eR_f$,

$-CH_2-CH_2-CHR_eR_f$, or R_g in which c is 1 or 2; R_c is thienyl,

25 thiazolyl (which may bear an amino substituent), isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridyl (which may bear an alkylsulphonyl, aminosulphonyl,

alkylaminosulphonyl, alkylaminocarbonyl, amino, amido, (1-4C)alkoxycarbonyl, carboxy, acetyl amino, chloro, fluoro,


30 cyano, (1-3C)alkyl, trifluoromethyl, methoxy, ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl or tetrazolyl

10030187-020402

substituent), pyrimidinyl, pyridazinyl, pyrazinyl or phenyl (which may bear a methyl, methylamino, dimethylamino, carboxy, dialkylaminosulphonyl, alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, alkylaminocarbonyl, amino, amido, 5 alkoxy, acetyl, chloro, fluoro, cyano, methoxy, ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl or tetrazolyl substituent); each of R_e and R_f independently is hydrogen or C_{1-3} alkyl; or CHR_eR_f is cyclopentyl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1- 10 3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 3- or 4-position), cyclohexyl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1- 3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 3- or 4-position), tetrahydropyran-4-yl, 15 tetrahydrothiopyran-4-yl, pyrrolidin-3-yl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 1-position), piperidin-4-yl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, 20 methoxycarbonyl or ethoxycarbonyl substituent at the 1-position), or indan-2-yl; and R_g is 2-methylsulphonylphenyl which may bear a 4-fluoro substituent or R_g is λ^6 -1,1-dioxobenzo[b]thiophen-7-yl;

or a physiologically-tolerable salt thereof;

25 provided that $Lp(D)_n$ is not of the formula (K):




wherein X_2 is fluoro or hydrogen.

30 compound according to claim 1

2. A ~~serine protease inhibitor compound of formula (I)~~

(amended)

- 173 -



wherein,

~~R₂ is a 5 or 6 membered aromatic carbon ring optionally~~
 5 interrupted by a nitrogen, oxygen or sulphur ring atom,
 optionally being substituted in the 3 and/or 4 position (in
 relation to the point of attachment of X-X) by halo, nitro,
 thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano,
 haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or
 10 difluoromethoxy, carboxy, acyloxy, MeSO₂- or R₁, or the
 substituents at the 3 and 4 positions taken together form a
 fused ring which is a 5 or 6 membered carbocyclic or
 heterocyclic ring optionally substituted by halo, haloalkoxy,
 haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl,
 15 alkynyl or R_{1j}, and optionally substituted in the position
 alpha to the X-X group (i.e. 6 position for a six membered
 aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy,
 alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio
 with the proviso that R₂ cannot be aminoisoquinolyl;

20 each X independently is a C, N, O or S atom or a CO,
 CR_{1a}, C(R_{1a})₂ or NR_{1a} group, at least one X being C, CO, CR_{1a}
 or C(R_{1a})₂;

each R_{1a} independently represents hydrogen or hydroxyl,
 alkoxy, alkyl, aminoalkyl, hydroxyalkyl alkoxyalkyl,
 25 alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino,
 acyloxymethoxycarbonyl or alkylamino optionally substituted by
 hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R₁ is as defined for R_{1a}, provided that R₁ is not
 unsubstituted aminoalkyl;

30 ~~Y (the α atom) is a nitrogen atom or a CR_{1b} group;~~

Cy is a saturated or unsaturated, mono or poly cyclic,
 homo or heterocyclic group, optionally substituted by groups


10030157-020402

R_{3a} or phenyl optionally substituted by R_{3a} ;

each R_{3a} independently is R_{1c} , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl;


~~R_{1b} , R_{1c} and R_{1j} are as defined for R_{1a} and~~

$-L-Lp(D)_n$ is of the formula:



in which R_r is $-(CH_2)_c-R_c$, $-CHR_eR_f$, $-CH_2-CHR_eR_f$, or R_g in which c is 1 or 2; R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2 , methylaminosulphonyl, dimethylaminosulphonyl, methoxy or methylsulphonyl substituent); each of R_e and R_f independently is hydrogen or C_{1-3} alkyl; or CHR_eR_f is cyclopentyl (which may bear a methyl, ethyl or hydroxymethyl substituent at the 3- or 4-position), cyclohexyl (which may bear a methyl, ethyl or hydroxymethyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 3- or 4-position), tetrahydropyran-4-yl, tetrahydrothiopyran-4-yl, pyrrolidin-3-yl (which may bear a 1-methyl substituent), or indan-2-yl; and R_g is 2-methylsulphonylphenyl which may bear a 4-fluoro substituent or R_g is λ^6 -1,1-dioxobenzo[b]thiophen-7-yl.

~~or a physiologically tolerable salt thereof, provided that $Lp(D)_n$ is not of the formula (K):~~




- 175 -

(K)

~~wherein X₂ is fluoro or hydrogen.~~

- 5 3. A compound according to claim 1 wherein -L-Lp(D)_n is of the formula:



in which R_f is -(CH₂)_c-R_C; in which c is 2; R_C is thienyl, thiazolyl (which may bear an amino substituent),
 10 isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridyl (which may bear an amino, methoxycarbonyl, carboxy, fluoro, cyano, methyl, methylsulphonyl, aminosulphonyl, methylaminosulfonyl, dimethylaminosulfonyl, or trifluoromethyl
 15 substituent), pyrimidinyl, pyridazinyl, pyrazinyl or phenyl (which phenyl may bear a fluoro, chloro, cyano, methyl, amino, methylsulphonyl, aminosulphonyl, methylaminosulphonyl, dimethylaminosulphonyl, methylamino, dimethylamino, carboxy, methoxycarbonyl or methoxy substituent).

(amended)

- 20 4. A compound according to ~~any one of claims 1 to 3~~ wherein R_C is thiazolyl (which may bear an amino substituent), pyrimidinyl, pyrazolyl, imidazolyl, pyridyl (which may bear a methylsulphonyl, aminosulphonyl, methylaminosulfonyl, dimethylaminosulfonyl, fluoro, cyano, methyl or
 25 trifluoromethyl substituent), pyridazinyl, pyrazinyl or phenyl (which phenyl may bear a fluoro, chloro, cyano, methyl, amino, methylamino, dimethylamino, carboxy, methoxycarbonyl, methylsulphonyl, aminosulphonyl, methylaminosulfonyl, dimethylaminosulfonyl, or methoxy substituent).

(amended)

- 30 5. A compound according to ~~any one of claims 1 to 4~~ wherein

Rc is thiazolyl (which may bear an amino substituent), pyrazolyl, imidazolyl, pyridyl (which may bear a fluoro, cyano, methyl or trifluoromethyl substituent), pyridazinyl or pyrazinyl.

5




(amended)

6. A compound according to ~~any one of claims 1 to 5~~ wherein Rc is thiazol-2-yl, 2-aminothiazol-4-yl, pyrazol-1-yl, pyrazol-4-yl, pyridazin-3-yl, imidazol-1-yl, imidazol-4-yl, pyrazin-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 3-fluoropyrid-4-yl, 2-cyanopyrid-4-yl, 2-methylpyrid-4-yl or 2-trifluoromethylpyrid-6-yl.

(amended)

L is CO and

7. A compound according to claim 1 wherein -Lp(D)n is of the formula:












10030187-020402

15

20

- 177 -




10030187 020402

5

10

- 178 -



wherein;


m represents 0 or 1;

5 X^0 represents CH or N; and


when R_3 is present as a substituent on an aromatic ring,
it is selected from hydrogen, alkylsulphonyl, aminosulphonyl,
alkylaminosulphonyl, alkylaminocarbonyl, amino, amido,
alkoxycarbonyl, acetyl amino, chloro, fluoro, cyano, methoxy,
10 ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl and
tetrazolyl; and

when R_3 is present as a substituent on a saturated ring,
it is selected from hydrogen, hydroxy, amino, (1-3C)alkoxy,
(1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl and
15 ethoxycarbonyl.

8. A compound according to claim 7 wherein $-Lp(D)_n$ is of the
formula:



- 179 -



wherein R_1 is hydrogen or (1-6C)alkyl.

(amended)


9. A compound according to ~~any one of claims 1 to 8~~ wherein R_2 is phenyl, thien-2-yl, naphthyl, indol-2-yl, indol-6-yl, benzo[b]furan-5-yl, benzo[b]thiophen-2-yl or benzimidazol-2-yl (each of which is optionally substituted as defined in claim 1).

(amended)

10. A compound according to ~~any one of claims 1 to 9~~ wherein optional substituents for R_2 are selected from: fluoro, chloro, bromo, iodo, nitro, thiol, difluoromethoxy, trifluoromethoxy, hydrazido, methylhydrazido, amino, cyano, trifluoromethyl, methylthio, vinyl, ethynyl, acetylamino, carboxy, acetoxy, hydroxy, methyl, ethyl, amido (CONH_2), aminomethyl, methoxy and ethoxy.

(amended)

11. A compound according to ~~any one of claims 1 to 10~~ wherein R_2 is selected from one of the formula (A') to (H'):



wherein X_4 is O or S, R_{13} is selected from hydrogen, fluoro, [except for (C')] chloro or methyl and R_{14} is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and
 5 R_{15} is selected from hydrogen, methyl, fluoro, chloro and amino.

(amended)

12. A compound according to claims ~~1 to 11~~, wherein R_2 is 4-chlorophenyl, 4-methoxyphenyl, 3-amino-4-chlorophenyl, indol-
 10 2-yl, 5-chloroindol-2-yl, indol-6-yl, 3-chloroindol-6-yl or 3-methylindol-6-yl.

(amended)

13. A compound according to ~~any one of claims 1 to 12~~ wherein

-X-X- is -CONH-.

(amended)

, 15 to 16 and 19 to 22

14. A compound according to any one of claims 1 to 13 wherein Y is CH.

5

(amended)

15. A compound according to ~~any one of claims 1 to 14~~ wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl, furanyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl,

10 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyrimidinyl, pyridazinyl, quinolyl, isoquinolyl, benzofuryl, benzothienyl or cycloalkyl group, or a phenyl group substituted by R_{3i}X_i in which X_i is a bond, O, NH or CH₂ and R_{3i} is phenyl, pyridyl or pyrimidyl optionally substituted by R_{3a}.

15

(amended)

16. A compound according to ~~any one of claims 1 to 14~~ wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl or cycloalkyl group.

(cancelled on national phase entry)

20 17. ~~A compound according to any one of claims 1 to 16 wherein R_{3a} is selected from hydrogen, hydroxyl, alkoxy, alkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), aminoalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), hydroxyalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, alkylamino (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S; and R¹¹ and R¹² are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which~~

10030187.020402

~~they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group) and -OCH₂O- which is bonded to two adjacent ring atoms in Cy~~

~~(cancelled on national phase entry)~~

- 5 18. ~~A compound according to any one of claims 1 to 16 wherein~~
~~R_{3a} is selected from hydrogen, hydroxyl, alkoxy, alkyl~~
~~(optionally substituted by hydroxy, alkylamino, alkoxy, oxo,~~
~~aryl or cycloalkyl), hydroxyalkyl (optionally substituted by~~
~~hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl),~~
10 ~~alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl,~~
~~alkoxycarbonylamino, alkylamino (optionally substituted by~~
~~hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl),~~
~~aminoalkyl (substituted by hydroxy, alkylamino, alkoxy, oxo,~~
~~aryl or cycloalkyl), amino, halo, cyano, nitro, thiol,~~
15 ~~alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido,~~
~~alkylaminosulphonyl, aminosulphenyl, haloalkoxy and haloalkyl~~

~~(amended)~~

15

19. ~~A compound according to any one of claims 1 to 16 wherein~~
~~R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy,~~
20 ~~methyl, ethyl, methylaminomethyl, dimethylaminomethyl,~~
~~hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl,~~
~~ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl,~~
~~aminomethyl, CONH₂, CH₂CONH₂, acetylamino,~~
~~methoxycarbonylamino, ethoxycarbonylamino, t-~~
25 ~~butoxycarbonylamino, amino, fluoro, chloro, bromo, cyano,~~
~~nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl,~~
~~methylsulphenyl, methylsulphonylamido, ethylsulphonylamido,~~
~~methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl,~~
~~trifluoromethoxy, trifluoromethyl, bromo, -OCH₂O- (which is~~
30 ~~bonded to two adjacent ring atoms in Cy) and -C(X³)N(R¹¹)R¹²~~
~~(wherein X³ is O or S and R¹¹ and R¹² are independently~~
~~selected from hydrogen, methyl or ethyl or together with the~~
~~nitrogen atom to which they are attached form a pyrrolidin-1-~~
~~yl, piperidin-1-yl or morpholino group).~~












10030187 020402

(amended)


20. / A compound according to ~~any one of claims 1 to 16~~ wherein
R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy,
methyl, ethyl, methylaminomethyl, dimethylaminomethyl,
5 hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl,
ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl,
aminomethyl, CONH₂, CH₂CONH₂, acetylamino,
methoxycarbonylamino, ethoxycarbonylamino, t-
butoxycarbonylamino, amino, fluoro, chloro, cyano, nitro,
10 thiol, methylthio, methylsulphonyl, ethylsulphonyl,
methylsulphenyl, methylsulphonylamido, ethylsulphonylamido,
methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl,
trifluoromethoxy and trifluoromethyl.

(amended)

- 15 21. / A compound according to ~~any one of claims 1 to 14~~ wherein
Cy is selected from:



or



wherein:

X' is selected from O, S and NMe;

X'' is selected from O and S;

X''' is selected from O, S, NH and NMe;

Y' is selected from hydrogen, amino and methyl;

R_o is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphanyl and methylsulphonyl;

R_m is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphanyl, methylsulphonyl, carboxy, methoxycarbonyl and a group of the formula $-C(X^3)N(R^{11})R^{12}$ (wherein X^3 is O or S and R^{11} and R^{12} are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group); R_p is selected from hydrogen and fluoro; or

- 185 -

R_O and R_m or R_m and R_p form an $-OCH_2O-$ group; or
 R_O and R_m together with the ring to which they are attached
 form a 5 or 6 membered aryl or heteroaryl ring (wherein the
 heteroaryl ring contains 1 or 2 heteroatoms selected from
 5 nitrogen, oxygen and sulfur);


one of R_{O1} and R_{O2} is hydrogen and the other is R_O ;

(amended)

22. A compound according to ~~any one of claims 1 to 14~~ wherein
 Cy is selected from phenyl, 2-chlorophenyl, 2-methoxyphenyl,
 10 4-carbamoylphenyl, pyrid-2-yl, pyrid-4-yl, thien-2-yl, thien-
 3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl,
 thiazol-4-yl, thiazol-5-yl and quinolin-4-yl.

(amended)


23. A compound of the formula:



or a physiologically-tolerable salt thereof, wherein Cy, R_2
 and R_c are as defined in ~~any one of claims 1 to 22~~.

(amended)

24. A compound of the formula:



or a physiologically-tolerable salt thereof, wherein Cy and R_2
 are as defined in ~~any one of claims 1 to 22~~.

(amended)

14

25. A compound as claimed in ~~any one of Claims 1 to 24~~, in
 which the alpha atom in Y is carbon and has the conformation
 that would result from construction from a D- α -aminoacid
 $NH_2-CR_{1b}(Cy)-COOH$ where the NH_2 represents part of X-X.

26. A compound as claimed in Claim 1, which is selected from:
1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[2-(4-pyridiny1)-
ethyl]piperazine;

5 1-(3-Chloroindole-6-carbonyl-D-phenylglyciny1)-
4-[2-(4-pyridiny1)ethyl]piperazine;

1-(4-Methoxybenzoyl-D-phenylglyciny1)-4-(1-methylpiperidin-4-
yl)piperazine;

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-(1-methylpiperidin-4-
10 yl)piperazine;

1-(4-Methoxybenzoyl-D-(2-chlorophenyl)glyciny1)-4-(1-methyl-
piperidin-4-yl)piperazine;

1-(Indole-6-carbonyl-D-(2-chlorophenyl)glyciny1)-4-(1-methyl-
piperidin-4-yl)piperazine; and

15 1-(4-Methoxybenzoyl-D-(2-trifluoromethylphenyl)glyciny1)-4-(1-
methylpiperidin-4-yl)piperazine;

and physiologically-tolerable salts thereof.

(amended)

20 27. A pharmaceutical composition, which comprises a compound
as claimed in ~~any one of~~ Claims 1 ~~to 26~~ together with at least
one pharmaceutically acceptable carrier or excipient.

(cancelled on national phase entry)

28. ~~A compound as claimed in any one of Claims 1 to 26, for
use in therapy.~~

25 *(cancelled on national phase entry)*

29. ~~Use of a compound as claimed in any one of Claims 1 to 26
for the manufacture of a medicament for the treatment of a
thrombotic disorder.~~

30 30. A method of treatment of a human or non-human animal body
to combat a thrombotic disorder, which comprises administering
to said body an effective amount of a compound as claimed in
claim 1.

10030187.020402

(cancelled on national phase entry)


31. ~~A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 26 for use to combat a thrombotic disorder.~~

(cancelled on national phase entry)

5 32. ~~A compound of formula I as claimed in claim 1 and named in any of the Examples herein, or a physiologically tolerable salt thereof.~~

(amended)

10 33. A compound of the formula



or a salt thereof.

in which Cy is as defined in claim 1,

10030187.020402